Latest Breaking News On - Vince angotti - Page 2 : vimarsana.com

AcelRx Receives IDE Approval for Niyad and Advances to a Single Registration Study

/PRNewswire/ AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of.

United statesVince angottiPamelap palmerAcelrx pharmaceuticals incDrug administrationInvestigational device exemptionAcelrx pharmaceuticalsUnited states foodChief executive officerChief medical officerBreakthrough device designationEmergency use authorizationBreakthrough device designation status

AcelRx Pharma (ACRX) Receives IDE Approval for Niyad and Advances to a Single Registration Study

AcelRx Pharma (ACRX) Receives IDE Approval for Niyad and Advances to a Single Registration Study
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesVince angottiPamelap palmerAcelrx pharmaceuticals incDrug administrationAcelrx pharmaceuticalsInvestigational device exemptionUnited states foodChief executive officerChief medical officerBreakthrough device designationEmergency use authorization

AcelRx Pharmaceuticals, Inc (NASDAQ:ACRX) Q2 2023 Earnings Call Transcript

Operator: Welcome to the AcelRx Second Quarter 2023 Financial Results Conference Call.

South koreaPam palmerThomas yipRaffi asadorianVince angottiEd arceUniversity of pittsburgh medical centerDepartment of defenseExchange commissionHealth photoUs armyAcelrx pharmaceuticals incDepartment of defense or doAlora pharmaceuticalsAcelrx pharmaceuticalsCall transcript august

AcelRx Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Capital raise closed in July, led by new healthcare investors; provides access to up to $26.3 million in capital, with $10 million immediately available AcelRx.

Vince angottiAcelrx pharmaceuticals incAlora pharmaceuticalsExchange commissionCompany annual report on formPrnewswire acelrx pharmaceuticals incNasdaq stock marketDepartment of defenseEmergency use authorizationChief executive officerBreakthrough designationRecent corporateNantahala capital managementUpcoming eventsAcelrx pharmaceuticalsBreakthrough device designation status

AcelRx Pharmaceuticals Announces Closing of Previously Announced Private Placement Priced At-The-Market under Nasdaq Rules

HAYWARD - AcelRx Pharmaceuticals, Inc. , , a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today.

United statesRaffi asadorianVince angottiAcelrx pharmaceuticals incDrug administrationHc wainwright coSecurities exchangeExchange commissionPre funded warrantsPre funded warrantsPre funded warrantSecurities actBreakthrough device designation statusSecurities exchange actNews publishing